Comparative proteomic analysis of irinotecan-sensitive colorectal carcinoma cell line and its chemoresistant counterpart

Anti-Cancer Drugs

Volumn 22, Issue 6, 2011, Pages 500-506

  Gong, Feng Ming ^a   Peng, Xing Chen ^a   Tan, Ben Xu ^a   Ge, Jun ^a   Chen, Xi ^a   Chen, Ye ^a   Xu, Feng ^a   Bi, Feng ^a   Hou, Jian Mei ^a   Liu, Ji Yan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

colorectal carcinoma; drug resistance; irinotecan; two dimensional gel electrophoresis

Indexed keywords

ALPHA ENOLASE; CHAPERONE; COFILIN; IRINOTECAN; MESSENGER RNA; THIOREDOXIN; THIOREDOXIN DEPENDENT PEROXIDE 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CARCINOMA; DRUG RESISTANCE; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ACTIN DEPOLYMERIZING FACTORS; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PHOSPHOPYRUVATE HYDRATASE; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 79958258433     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283408596     Document Type: Article

References (36)

1. Greenlee RT, Murray T, Bolden S, Wingo PS. Cancer Statistics, 2000. CA Cancer J Clin 2000; 50:7-33.
2. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
3. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23:4553-4560. (Pubitemid 46196586)
4. Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist 2006; 11:981-987. (Pubitemid 44564805)
5. Rothenberg ML. Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 2001; 6:66-80. (Pubitemid 32155817)
6. Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, Jansen WJ, Pinedo HM, et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 1998; 77:2171-2176. (Pubitemid 28263937)
7. Takahashi T, Fujiwara Y, Yamakido M, Katoh O,Watanabe H, Mackenzie PI. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn J Cancer Res 1997; 88:1211-1217. (Pubitemid 28048269)
8. Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance associated protein, MRP. Eur J Cancer 1996; 32A:945-957.
9. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP, et al. Mechanism of action of camptothecin. Ann N Y Acad Sci 2000; 922:1-10. (Pubitemid 32050237)
10. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A. Inhibition of JNK activation through NF-kappaB target genes. Nature 2001; 414:313-317. (Pubitemid 33097808)
11. Lage H. Proteomics in cancer cell research: an analysis of therapy resistance. Pathol Res Pract 2004; 200:105-117. (Pubitemid 38950440)
12. Righetti PG, Castagna A, Antonioli P, Cecconi D, Campostrini N, Righetti SC. Proteomic approaches for studying chemoresistance in cancer. Expert Rev Proteomics 2005; 2:215-228. (Pubitemid 40529860)
13. Rabilloud T, Adessi C, Giraudel A, Lunardi J. Improvement of the solubilization of proteins in two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 1997; 18:307-316. (Pubitemid 27174413)
14. Gorg A, PostelW,Weser J, Gunther S, Strahler JR, Hanash SM. Elimination of point streaking on silver-stained two-dimensional gels by addition of iodoacetamide to the equilibration buffer. Electrophoresis 1987; 8:122-124.
15. Hütter G, Sinha P. Proteomics for studying cancer cells and the development of chemoresistance. Proteomics 2001;1: 1233-1248.
16. Pancholi V. Multifunctional a-enolase: its role in diseases. Cell Mol Life Sci 2001; 58:902-920. (Pubitemid 32652817)
17. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 2001; 11:41-47. (Pubitemid 32119276)
18. Gilberger TW, Bergmann B, Walter RD, Müller S. The role of the C-terminus for catalysis of the large thioredoxin reductase from Plasmodium falciparum. FEBS Lett 1998; 425:407-410. (Pubitemid 28178841)
19. Matsuda M, Masutani H, Nakamura H, Miyajima S, Yamauchi A, Yonehara SC, et al. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J Immunol 1991; 147:3837-3841.
20. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002; 277:37169-3775.
21. Mialhe A, Louis J, Pasquier D, Rambeaud JJ, Seigneurin D. Expression of three cell adhesion molecules in bladder carcinomas: correlation with pathological features. Anal Cell Pathol 1997; 13:125-136. (Pubitemid 27315909)
22. Pittenger MF, Kazzaz JA, Helfman DM. Functional properties of non-muscle tropomyosin isoforms. Curr Opin Cell Biol 1994; 6:96-104. (Pubitemid 24048701)
23. Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS. Cofilin promotes actin polymerization and defines the direction of cell motility. Science 2004; 304:743-746. (Pubitemid 38560882)
24. Mouneimne G, Soon L, DesMarais V, Sidani M, Song X, Yip SC, et al. Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation. J Cell Biol 2004; 166:697-708. (Pubitemid 39181007)
25. Desmarais V, Ghosh M, Eddy R, Condeelis J. Cofilin takes the lead. J Cell Sci 2005; 118:19-26. (Pubitemid 40277101)
26. Chua BT, Volbracht C, Tan KO, Li R, Yu VC, Li P. Mitochondrial translocation of cofilin is an early step in apoptosis induction. Nat Cell Biol 2003; 5:1083-1089. (Pubitemid 37509115)
27. Tamura T, Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci USA 1996; 93:1006-1011. (Pubitemid 26054364)
28. Gladyshev VN, Jeang KT, Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci USA 1996; 93:6146-6151. (Pubitemid 26190818)
29. Sun Y, Oberley LW. Redox regulation of transcriptional activators. Free Radic Biol Med 1996; 21:335-348. (Pubitemid 26271723)
30. Spyrou G, Holmgren A. Deoxyribonucleoside triphosphate pools and growth of glutathione-depleted 3T6 mouse fibroblasts. Biochem Biophys Res Commun 1996; 220:42-46. (Pubitemid 26106796)
31. Andersson M, Holmgren A, Spyrou G. NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase. Implication for a protective mechanism against NKlysin cytotoxicity. J Biol Chem 1996; 271:10116-10120.
32. Mustachich D, Powis G. Thioredoxin reductase. Biochem J 2000; 346:1-8. (Pubitemid 30113812)
33. Arscott LD, Gromer S, Schirmer RH, Becker K, Williams CH Jr. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc Natl Acad Sci USA 1997; 94:3621-3626.
34. Gromer S, Schirmer RH, Becker K. The 58 kDa mouse selenoprotein is a BCNU-sensitive thioredoxin reductase. FEBS Lett 1997; 412: 318-320. (Pubitemid 27321274)
35. Schallreuter KU, Gleason FK, Wood JM. The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim Biophys Acta 1990; 1054:14-20. (Pubitemid 20247791)
36. Sasada T, Nakamura H, Ueda S, Sato N, Kitaoka Y, Gon Y, et al. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med 1999; 27:504-514. (Pubitemid 29408635)